Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Safian

Cardiovascular Disease Royal Oak, MI Medical Doctor

NPI 1588646707 CMS profile 344230

3601 W 13 Mile Rd, Beaumont Academic Heart And Vascular, Royal Oak, MI 48073

Open in the dashboard

General payments

$25,658

92 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Safian of Royal Oak, MI is reported in the CMS Open Payments database as having received $25,658 across 92 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $13,978 44
2024 General $1,571 14
2023 General $8,546 12
2022 General $370 4
2021 General $77 1
2020 General $288 4
2019 General $829 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Safian
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Robert Safian were reported at $13,978. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Robert Safian Cardiovascular Disease median Middle half National median
2019 $829 $450 $127–$1,392 $163
2020 $288 $242 $77–$751 $114
2021 $77 $335 $101–$1,037 $132
2022 $370 $395 $121–$1,211 $149
2023 $8,546 $443 $136–$1,283 $160
2024 $1,571 $450 $136–$1,323 $164
2025 $13,978 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $14,170 55 payments
  2. HeartFlow, Inc. $8,108 16 payments
  3. Boston Scientific Corporation $2,111 4 payments
  4. Medtronic Vascular, Inc. $715 11 payments
  5. Shockwave Medical, Inc $176 1 payment
  6. Siemens Medical Solutions USA, Inc. $153 1 payment
  7. AstraZeneca Pharmaceuticals LP $125 1 payment
  8. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $100 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $8,544 8 payments
  2. Travel and Lodging $7,776 17 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,825 3 payments
  4. Food and Beverage $4,513 64 payments
Products named General payments · program years 2019–2025
  1. FFRct $7,985 12 payments
  2. SYMPLICITY G3 $6,611 32 payments
  3. COREVALVE EVOLUT R $6,597 13 payments
  4. AVVIGO Guidance System $2,063 2 payments
  5. CoreValve Evolut Transcatheter Valve Systems $715 11 payments
  6. ONYX FRONTIER $641 5 payments
  7. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $176 1 payment
  8. LifeVest $100 3 payments
  9. CoreValve Evolut Transcatheter Valve Systems $77 1 payment
  10. Micra $66 1 payment
  11. Other $49 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

331

Median for Cardiology: 2,533

Drug cost

$58,424

Median for Cardiology: $485,213

Branded share of claims

41.7%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 20 $22,232
Repatha Sureclick Evolocumab Brand 27 $18,780
Praluent Pen Alirocumab Brand 21 $11,297
Clopidogrel Clopidogrel Bisulfate Brand 70 $1,549
Prasugrel Hcl Generic 14 $1,379
Ezetimibe Generic 28 $805
Atorvastatin Calcium Generic 32 $731
Rosuvastatin Calcium Generic 29 $592
Metoprolol Succinate Generic 20 $458
Carvedilol Generic 22 $216

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$72,193

Medicare's payments for the services billed

Medicare patients

334

Average age 75

Services billed

656

159 women, 175 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Arthritis 59%
Heart failure 48%
Atrial fibrillation 43%
Diabetes 42%
Chronic kidney disease 37%
Depression 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

92 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record